The group's principal activities are to conduct research, develop and commercialize transcription factors for regulation of gene expression. The group's gene recognition-tm- technology platform is a proprietary technology enabling the engineering of a class of transcription factors known as zinc finger dna-binding proteins (zfps). Universal gene recognition enables the technology, which is widely applicable to pharmaceutical discovery, development of human therapeutics, clinical diagnostics and plant agricultural and industrial biotechnology. The group intends to commercialize its technology on its applications. The group operates only in domestic market.
Executive Information
Name
Title
Email
Carl Pabo
Chmn. - Scientific Advisory Board
N/A
Edward Lanphier
Founder, CEO, Pres.
N/A
Dale Ando
VP - Therapeutic Development, Chief Medical Officer
